Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma : Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy - Zandberg, Dan P. (University of Pittsburgh Medical Center. Hillman Cancer Center) ; Algazi, Alain P. (University of California San Francisco Helen Diller Family Comprehensive Cancer Center) ; Jimeno, Antonio (Division of Medical Oncology. University of Colorado School of Medicine) ; Good, James S. (Institute of Head and Neck Studies and Education. Queen Elizabeth Hospital) ; Fayette, Jérôme (Clinical Oncology. Cancer Center Centre Léon Bérard. University of Lyon) ; Bouganim, Nathaniel (Department of Oncology. McGill University Health Centre) ; Ready, Neal E. (Duke University Medical Center) ; Clement, Paul M. (Department of Oncology. Leuven Cancer Institute) ; Even, Caroline (Institut Gustave Roussy (Villejuif, França)) ; Jang, Raymond W. (Princess Margaret Cancer Centre. University of Toronto) ; Wong, Stuart (Division of Hematology Oncology. Medical College of Wisconsin) ; Keilholz, Ulrich (Charité Comprehensive Cancer Center) ; Gilbert, Jill (Henry-Joyce Cancer Clinic) ; Fenton, Moon (The West Cancer Center. University of Tennessee Health Science Center) ; Braña, Irene (Vall d'Hebron Institut d'Oncologia) ; Henry, Stephanie (Department of Oncology-Hematology. Radiotherapy. and Nuclear Medicine. CHU UCL Namur) ; Remenar, Eva (National Institute of Oncology (Országos Onkológiai Intézet)) ; Papai, Zsuzsanna (State Health. Center Higatian Defanse Forses) ; Siu, Lillian L. (Princess Margaret Cancer Centre. University of Toronto) ; Jarkowski, Anthony (AstraZeneca) ; Armstrong, Jon M. (AstraZeneca) ; Asubonteng, Kobby (AstraZeneca) ; Fan, Jean (AstraZeneca) ; Melillo, Giovanni (AstraZeneca) ; Mesía, Ricard (Institut d'Investigació Biomèdica de Bellvitge) ; Universitat Autònoma de Barcelona